Connect with us

Business

FDA Approval of New Alzheimer’s Drug May Boost Prospects of Other Treatments – The Wall Street Journal

The FDA’s reasoning for greenlighting Biogen’s Aduhelm could bode well for other Alzheimer’s drugs targeting the disease in a…

Published

on

Article feature image
ADVERTISEMENT

The Food and Drug Administrations approval of Biogen Inc.s Aduhelm on Monday may have boosted the prospects of other experimental Alzheimers disease drugs that target the disease in a similar way.
In greenlighting Aduhelm, the FDA endorsed a hypothesis…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
A fantasy league bet that ended with 15-hour Waffle House trip – ESPN
Article feature image
Gas stations empty as driver shortage delays deliveries – KOAA.com Colorado Springs and Pueblo News
Article feature image
APS customers in Glendale experiencing power outage amid heat wave – ABC15 Arizona